Clinical trials: Substance Related Disorder
- Condition Substance Related Disorder
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Prescription Drug Abuse (Not Dependent), Substance Use
Preventing Prescription Drug Abuse in Middle School Students
This project is designed to test a primary prevention approach to the problem of prescription drug misuse and abuse (PDA) among middle school students.
- Conditions
- Prescription Drug Abuse (Not Dependent), Substance Use, Substance Abuse
- Trial name
- MSPDA (NCT03129334)
- Testing
- LST Middle School Online
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- National Health Promotion Associates, Inc.
Neonatal Opioid Withdrawal Syndrome, Neonatal Abstinence Syndrome
Neurostimulation to Improve NOWS Outcomes
The objective of this study is to determine if tAN therapy can reduce the median number of days of oral morphine administered to an infant after start of treatment.
- Trial name
- SPROUT (NCT05129020)
- Testing
- Sparrow Fledging Therapy System
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Spark Biomedical, Inc.
Substance Use, Substance Abuse
Mobile Technology to Reduce Teen Substance Misuse
The goal of this study is to test the newly expanded WisePath for Teens (WPT) for substance use app, a direct-to-consumer paired mobile phone app for iOS and Android platforms that supports parents/guardians in delivering…
- Conditions
- Substance Use, Substance Abuse, Suicide, Adolescent
- Trial name
- NCT05897164
- Testing
- WisePath for Teens, Peer Support Services (PSS), Control
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Pain, Pain, Acute
Assessing Opioid Care Practices Using CPV Patient Simulation Modules
This study will test the quality of opioid-related physician care decisions using a patient-simulation based measurement and feedback approach that combines multiple-choice care decisions with real-time, personalized scoring and…
- Conditions
- Pain, Pain, Acute, Pain, Chronic, Pain, Neuropathic
- Trial name
- NCT04080037
- Testing
- Quality IQ Patient Simulations
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Alcohol Dependence
Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence
The purpose of this study is to investigate the safety and the prognosis after achieving reduced alcohol intake in patients with alcohol dependence who received treatment for the reduction of alcohol intake in the routine…
- Trial name
- NCT04107051
- Testing
- Nalmefene Hydrochloride Hydrate
- Where
- Japan
- Volunteers
- 533 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Opioid Related Disorders, Opiate Addiction
Evaluation of Changes in Prescribing Behavior of ER/LA Opioid Prescribers
A study will be performed to evaluate changes in prescribing behavior of prescribers of ER/LA opioids
- Conditions
- Opioid Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02920762
- Testing
- on-interventional study - retrospective database review
- Volunteers
- 5,575,834 people
- Sponsor
- ER/LA Opioid REMS Program Companies (RPC)
Opioid Withdrawal (Disorder), Opioid Use Disorder
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects
The goal of this clinical study is to evaluate the pharmacokinetic (PK), safety, and tolerability of LUCEMYRA in adolescents age ≥12 to <18 years old abruptly discontinuing opioid use.
- Trial name
- NCT06711640
- Testing
- LUCEMYRA (lofexidine) tablets
- Where
- United States
- Sponsor
- USWM, LLC (dba US WorldMeds)
Opioid Induced Constipation
Naloxegol Drug Utilization Post Authorisation Safety Study
This post-authorization observational safety study determines the characteristics of patients prescribed naloxegol at time of first prescription and treatment patterns of naloxegol in follow-up in the United Kingdom (UK), Norway…
- Trial name
- NCT02813148
- Testing
- Naloxegol
- Where
- 4 sites in Germany, Norway and 2 more
- Volunteers
- 17,254 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Opioid-related Disorders, Opioid Addiction
ER/LA Opioid Analgesics - Surveillance Monitoring of State Medical Examiner Databases
In April 2011, the U.S. Food and Drug Administration (FDA) determined that a class-wide risk evaluation and mitigation strategy (REMS) for all extended-release (ER) and long-acting (LA) opioid medications was necessary to support…
- Conditions
- Opioid-related Disorders, Opioid Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02897414
- Testing
- Surveillance of state medical examiner databases
- Volunteers
- 13,015 people
- Sponsor
- ER/LA Opioid REMS Program Companies (RPC)
Opioid-Related Disorders, Opiate Dependence
Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)
The purpose of this study is to evaluate the acceptability and safety of switching to Suboxone® (buprenorphine plus naloxone) and the effect of the switch on medication dispensing.
- Conditions
- Opioid-Related Disorders, Opiate Dependence, Drug Abuse
- Trial name
- NCT00725608
- Testing
- buprenorphine/naloxone
- Where
- Austria
- Volunteers
- 339 people
- Sponsor
- Indivior Inc.
Substance Use
Online System for Primary Care to Prevent and Address Teen Substance Use
This Quality Improvement (QI) project for physician education will build on an existing platform, CHADIS (Comprehensive Health and Decision Information System; www.CHADIS.com).
- Trial name
- Substance (NCT04689997)
- Testing
- cSBI
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Total Child Health, Inc.
Opioid Related Disorders, Opiate Addiction
Evaluation of Drug Utilization Patterns for Extended Release/Long Acting Opioids and Comparator Products
A drug utilization study will be performed to describe trends in the number of prescriptions and patients for class REMS ER/LA opioids and comparator products.
- Conditions
- Opioid Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02925806
- Testing
- Non-interventional study - retrospective database review
- Volunteers
- 5,575,834 people
- Sponsor
- ER/LA Opioid REMS Program Companies (RPC)
Job Satisfaction, Work Performance
Life Skills Training Workplace Prevention Program
A workplace health promotion intervention for youth age 16-24
- Conditions
- Job Satisfaction, Work Performance, Health Care Utilization, Depression Symptoms
- Trial name
- LST-WP (NCT06745739)
- Testing
- Life Skills Training Workplace Prevention Program
- Volunteers
- 1,145 people, healthy volunteers welcome
- Sponsor
- National Health Promotion Associates, Inc.
Prescription Opioid Misuse
Reducing High School Athletes' Prescription Opioids Misuse and Diversion Through the Student Athlete Wellness Portal
The goal of this study is to prevent prescription opioid misuse among high school athletes by developing, demonstrating the feasibility, and evaluating the outcomes of an innovative digital intervention.
- Trial name
- NCT05209191
- Testing
- Student Athlete Wellness Portal
- Where
- 5 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Real Prevention, LLC
Substance-Related Disorders
Arise: An Online Relapse Prevention Tool for Adolescent Substance Abusers
In Phase I of this SBIR project, 3C Institute (3C) developed a working prototype of an innovative computer-based coping skills educational program for adolescent substance abuse treatment completers.
- Trial name
- ARISE (NCT02715557)
- Testing
- Relapse prevention program
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- 3-C Institute for Social Development
Bullying, Cyberbullying
An Evidence-based Approach for Bullying Prevention
This Phase II SBIR project is designed to address the critical public health problem of bullying and cyberbullying among middle school age youth.
- Conditions
- Bullying, Cyberbullying, Substance Use, Substance Abuse
- Trial name
- NCT03205059
- Testing
- LST MS curriculum+ Bullying/Cyberbulling serious game, LST MS curriculum
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- National Health Promotion Associates, Inc.
Opioid Addiction, Opioid Abuse, Continuous Use
Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction
Healthy adult human male facial skin surface lipid liquid pheromone given by mouth to opioid addicts cures them without any withdrawal symptoms whatsoever 250mg on chewing gum vehicle by mouth.
- Conditions
- Opioid Addiction, Opioid Abuse, Continuous Use, Opioid Use, Opioid-Related Disorders
- Trial name
- NCT03394911
- Testing
- 250mg healthy adult male facial skin surface lipid liquid pheromone
- Volunteers
- 500 people
- Sponsor
- Bubba Nicholson
Substance Use
Interactive Technology for Media Literacy Drug Prevention in Community Groups
This Phase II STTR will evaluate an interactive, self-paced, e-learning media literacy intervention, REAL media, to prevent youth substance use among youth in the 4-H organization.
- Trial name
- NCT03157700
- Testing
- REAL media curriculum
- Where
- United States
- Volunteers
- 642 people, healthy volunteers welcome
- Sponsor
- Real Prevention, LLC
Opioid-Related Disorders, Opiate Dependence
Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)
The aim of this post marketing surveillance study is to investigate the retention rate after 12 months of drug dependence treatment with SUBOXONE® (buprenorphine plus naloxone) of opioid dependent patients under real life…
- Conditions
- Opioid-Related Disorders, Opiate Dependence, Drug Abuse
- Trial name
- NCT00723749
- Testing
- Buprenorphine/Naloxone
- Volunteers
- 384 people
- Sponsor
- Indivior Inc.
Attention Deficit Hyperactivity Disorder, Cannabis Abuse
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse.
- Trial name
- PEACE (NCT00687609)
- Testing
- Atomoxetine
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company